CN115634250B - She medicine phlegm-resolving superfine powder patch and preparation method thereof - Google Patents
She medicine phlegm-resolving superfine powder patch and preparation method thereof Download PDFInfo
- Publication number
- CN115634250B CN115634250B CN202211346714.9A CN202211346714A CN115634250B CN 115634250 B CN115634250 B CN 115634250B CN 202211346714 A CN202211346714 A CN 202211346714A CN 115634250 B CN115634250 B CN 115634250B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- resolving
- phlegm
- superfine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a she medicine phlegm-resolving superfine powder patch, which comprises the following medicinal components in parts by weight: 45-55 parts of cold tea (she), 45-55 parts of melastoma dodecandrum, 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia, 10-20 parts of lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice; the ultra-micro powder acupoint ultrasonic penetration of the she medicine phlegm-resolving formula can obviously improve the traditional Chinese medicine syndrome integration of the patient with phlegm-heat accumulation lung type wind-warm lung-heat disease, effectively reduce the lung infection CPIS score and relevant inflammatory indexes (N%, CRP and PCT) of the patient, effectively improve the clinical curative effect, and is worthy of clinical popularization and application.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a she medicine phlegm-resolving superfine powder patch.
Background
The symptoms of wind-warm lung-heat disease due to phlegm-heat obstructing the lung are as follows: the symptoms of high fever, cough, yellow and thick sputum, cough and rust colored sputum, chest pain, shortness of breath, thirst and dysphoria, yellow and red urine, dry stool or constipation, red tongue with yellow coating, and rapid and slippery pulse.
The disease is treated by western medicines, a plurality of treatment courses are often needed to achieve a better treatment effect, and patients are recovered slowly, so that the she medicine phlegm-resolving superfine powder patch with an auxiliary treatment effect is necessary to be provided, and the clinical curative effect is improved.
Disclosure of Invention
The invention aims to provide a she medicine phlegm-resolving superfine powder patch for solving the problems in the background technology.
In order to achieve the above purpose, the present invention provides the following technical solutions:
the she medicine phlegm-resolving prescription superfine powder patch comprises the following medicinal components in parts by weight: 45-55 parts of cold tea (she), 45-55 parts of melastoma dodecandrum, 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia, 10-20 parts of lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice.
The she medicine phlegm-resolving superfine powder patch comprises the following medicinal components in parts by weight: 50 parts of cold tea (she), 50 parts of melastoma, 15 parts of ephedra herb, 30 parts of almond, 15 parts of ginger processed pinellia, 15 parts of lute leaf, 10 parts of borneol and 10 parts of liquorice.
The medicine of the she medicine phlegm-resolving superfine powder patch is dried at the temperature of 60 ℃, is mixed after superfine grinding, is mixed with 45 parts of honey, 50 parts of water and 0.95 part of cool tea oil by weight to form an ointment, and is coated on an ultrasonic-guided cotton piece before use to prepare the she medicine phlegm-resolving superfine powder patch.
The she medicine phlegm-resolving superfine powder patch has the diameter of 3.7cm and the thickness of 2mm, and the weight of each she medicine phlegm-resolving superfine powder patch traditional Chinese medicine ointment is 4g.
Compared with the prior art, the invention has the beneficial technical effects that,
the ultra-micro powder acupoint ultrasonic penetration of the she medicine phlegm-resolving formula can obviously improve the traditional Chinese medicine syndrome integration of the patient with phlegm-heat accumulation lung type wind-warm lung-heat disease, effectively reduce the lung infection CPIS score and relevant inflammatory indexes (N%, CRP and PCT) of the patient, effectively improve the clinical curative effect, and is worthy of clinical popularization and application.
Detailed Description
The invention will be further illustrated with reference to specific examples.
The she medicine phlegm-resolving prescription superfine powder patch comprises the following medicinal components in parts by weight: 45-55 parts of cold tea (she), 45-55 parts of melastoma dodecandrum, 10-20 parts of ephedra, 25-35 parts of almond, 10-20 parts of ginger processed pinellia, 10-20 parts of lute leaf, 5-15 parts of borneol and 5-15 parts of liquorice.
The she medicine phlegm-resolving superfine powder patch comprises the following medicinal components in parts by weight: 50 parts of cold tea (she), 50 parts of melastoma, 15 parts of ephedra herb, 30 parts of almond, 15 parts of ginger processed pinellia, 15 parts of lute leaf, 10 parts of borneol and 10 parts of liquorice.
The herbal tea is a specific medicinal material of she nationality, and is currently received in 2015 edition Zhejiang province Chinese medicine processing Specification.
The medicine of the she medicine phlegm-resolving superfine powder patch is dried at the temperature of 60 ℃, is mixed after superfine grinding, is mixed with 45 parts of honey, 50 parts of water and 0.95 part of cool tea oil by weight to form an ointment, and is coated on an ultrasonic-guided cotton piece before use to prepare the she medicine phlegm-resolving superfine powder patch.
The ultrasonic-guided cotton piece product of the invention is named electrode for physiotherapy, and is purchased from Henan province and medical equipment limited company, and the model is ZLD-002.
Superfine grinding is an operation technology in the prior art, which overcomes the cohesive force inside the solid by using a mechanical or hydrodynamic method to crush the solid, so as to crush the material particles with the diameter of more than 3 mm to 10-25 microns.
The she medicine phlegm-resolving superfine powder patch has the diameter of 3.7cm and the thickness of 2mm, and the weight of each she medicine phlegm-resolving superfine powder patch traditional Chinese medicine ointment is 4g.
Clinical experimental data of she medicine phlegm-resolving superfine powder patch
1. Case selection
78 cases of patients with phlegm-heat obstructing lung type wind-warm lung-heat disease conforming to the study inclusion standard are randomly divided into 39 cases of control groups and test groups, wherein the control groups adopt conventional Western medical treatment and nursing; the test group carries out the ultrasonic penetration treatment of the superfine powder patch of the medicine for resolving phlegm on Feishu acupoint, pishu acupoint and Shenshu acupoint on the basis of the control group. Each acupoint is interfered for 1 time every day, and 10 days is a treatment course. The effectiveness of the intervention of the two groups of patients is compared, and each index change of the patients before the intervention and on the 5 th day of the intervention and on the 10 th day of the intervention is observed.
2. Diagnostic criteria
2.1 Western diagnostic criteria
Reference is made to diagnostic criteria in the chinese adult community guidelines for diagnosis and treatment of acquired pneumonia (version 2018).
(1) Community morbidity. (2) pneumonia-related clinical manifestations: (1) cough, expectoration or exacerbation of the symptoms of the original respiratory disease, with or without chest pain, purulent sputum, dyspnea and hemoptysis; (2) heating; (3) lung wetting syndrome; (4) WBC of less than 4 x 10 9 /L or above 10×10 9 L; (3) Chest imaging shows the appearance of new variegated infiltrations, leaf or segment solid shadows, frosted shadows or interstitial changes, with or withoutPleural effusion.
The clinical diagnosis can be established by excluding tuberculosis, lung tumor, pulmonary embolism and the like according to any one of the items (1), (3) and (2).
2.2 diagnostic criteria for TCM
Referring to the diagnosis standard of wind-warm lung-heat disease, the Chinese people's republic of China, the Chinese medicine industry standard, the diagnosis and treatment standard of internal medical science diseases (ZY/T001.1-94); the diagnosis basis (1) is mainly symptoms of fever, cough, polydipsia, or chest pain accompanied by qi urgency. (2) Serious patients can have symptoms of strong heat, flushed face, dysphoria, coma and delirium, even cold limbs and the like. (3) The disease is frequent in winter and spring, and has the characteristics of urgent onset, rapid transmission and short course of disease. (4) The patients with the total number of blood white cells and the increase of neutrophils belong to bacterial infection. (5) The lung can be seen as a sign of a real condition, or auscultation can be audible and dry and wet rotunding. (6) sputum smear or sputum culture can be used to detect pathogens. (7) Chest radiographs or radiographs, one or both lung lobes or inflammatory shadows of lung segments can be seen.
2.3 diagnostic criteria for syndrome
Main symptoms are as follows: cough, yellow phlegm or white and dry and sticky phlegm. Secondary symptoms: fever, shortness of breath, inappetence, cough, dyspnea, chest pain, fullness in chest and hypochondrium, cough and pain, phlegm in the throat, sticky and yellow phlegm, debilitation, red tongue with yellow coating, slippery and rapid pulse. Can be diagnosed by having 2 main symptoms or 1 main symptom plus 2 secondary symptoms.
3. Inclusion criteria
3.1 meets the diagnosis standard of Chinese and Western medicine
3.2 patients with light and moderate CAP
3.3 ages 18-80 years
3.4 operation site skin is intact and unbroken
3.5 syndrome score is greater than or equal to 4 points and CPIS score is greater than or equal to 4 points
3.6 awareness of the study and endorsement of consent
4. Exclusion criteria
4.1 complicated with severe viscera dysfunction, patients with serious primary diseases such as endocrine system and hematopoietic system, severe infection, and malignant tumor
4.2 combining acute myocardial infarction, cardiogenic shock, severe ventricular arrhythmias, obstructive cardiomyopathy, unrepaired valvular disease, constrictive pericarditis, pericardial tamponade, pulmonary embolism patients
4.3 unstable angina pectoris or myocardial infarction occurring in about 1 month
4.4 pregnant or lactating women
4.5 patients with mental medical history
4.6 drug allergy or contraindications
4.7 medicine for affecting immune function taken orally for 3 months
4.8 poor compliance, refusal of the study treatment more than or equal to 1 time
4.9 patients undergoing other trials simultaneously
5. Index of termination of falling off
5.1 Exit from the middle due to intolerance
5.2 changes in the condition require a transition from the branch of academic or vocational study
5.3 patients suffering from drug allergy such as redness and itching
6. Grouping method
Random cards were made from a random number table generated by SPSS 23.0. And then sealing the random cards one by a special person by using a sealed opaque envelope, randomly extracting the envelopes according to the test sequence of the tested patient, opening the envelopes under the witness of the special person, and carrying out grouping treatment according to the cards in the envelopes. They were divided into control and test groups. Baseline calibration was performed to ensure that there were no statistical differences in general data for age, sex, smoking history, body mass index, underlying disease, etc. Each group is interfered by a corresponding scheme and is strictly executed.
7. Data collection method
Before intervention: baseline data are collected before the intervention study formally starts, two trained nurses (responsible group length) communicate with patients and families, the study purpose, the content and the meaning are informed, after the patients and the families are matched and signed with 'informed consent' are obtained, general data such as age, sex, body mass index and the like of the patients are collected face to face, and data such as traditional Chinese medicine syndrome score, lung infection CPIS score, inflammatory index and the like are collected. The attention and the expression are unified when collecting data, and the data are filled in by the patient; when the patient cannot fill out by himself, the patient can be assisted in completing the filling content in the forms of inquiry, explanation and the like.
Dry prognosis: related data on day 5, day 10 of intervention was still collected by the two nurses.
8. Sample size estimation
The PASS15.0.5 software is adopted to estimate the sample size, alpha=0.1 and beta=0.2, the ratio of the case number proportion of the test group to the case number proportion of the control group is 1:1, the effective rate is taken as a main ending index, 68 samples are required for two groups according to the early pre-experiment result (the effective rate of the test group is 90% and the effective rate of the control group is 70%), the 15% drop rate is increased, the sample size is 78, and 39 samples are taken into each group.
9. Therapeutic materials
Instrument: an ultrasonic pulse conductivity therapeutic instrument SLC-005;
electrode for physiotherapy: model ZDL-002 Sanlang plate electrode cotton piece;
the she medicine phlegm-resolving superfine powder paste: the diameter is 3.7cm, the thickness is 2mm, and each tablet is about 4g self-made.
10. Treatment and nursing method
10.1 control intervention protocol
Refer to the guidelines for diagnosis and treatment of adult CAP in China (2018 edition), issued by the respiratory disease division of the Chinese medical society. Expectorant: ambroxol hydrochloride 15mg is instilled intravenously once daily; spasmolytic: doxofylline for injection 0.3g is instilled intravenously once daily; the nursing measures are used for taking oxygen inhalation, cooling, back beating, effective cough and expectoration guiding and other symptomatic nursing measures according to community acquired pneumonia nursing routine, guiding patients to drink more water, high protein light diet, lip contraction and breathing, and keeping mood smooth and other western medicine nursing measures.
10.2 trial group intervention protocol:
she medicine phlegm-resolving superfine powder is adopted to stick on acupoint ultrasonic penetration on the basis of the intervention scheme of the control group.
10.2.1 construction and training of intervention teams
(1) The conditions of the implementation personnel are as follows: the system has a subject group member for executing qualification by a traditional Chinese medicine nursing technology, and qualified personnel are trained and checked uniformly.
(2) The theoretical training content is the composition of the medicines, the positioning, the action, the acupoint selection method and the like of related acupoints. According to the composition of the medicines, the data of medicine names, medicine properties, channel tropism, main application methods, clinical use experience and the like of the medicines in the research are arranged for training use by consulting Chinese she medicine and Chinese medicine published by Chinese traditional medicine publishing society and consulting related documents; the method for locating, acting and selecting the acupoints is referred to the national standard of the people's republic of China, namely the acupoint name and location (GB/T12346-2006), and the method for locating, acting and selecting the acupoints related to learning by the teaching materials of the national university of Chinese traditional medicine, namely the national advanced, namely the national academy of Chinese traditional medicine.
(3) Operation training
(1) The operation training is carried out according to the operation scoring standard of ultrasonic medicine penetration treatment, and the teacher is taught to fix one person, so that the medical nursing backbone talents in Zhejiang province are provided.
(2) Recording video for learning in the process of manufacturing the she medicine phlegm-resolving superfine powder patch; the operation processes of medicine mixing, dosing, coating and the like all need to pass through examination after training and work under the guidance of a full-time quality controller (she medical research institute master pharmacist).
(3) The nurses are required to carry out skilled operation, the accuracy of key links such as she medicine phlegm reduction superfine powder plaster, acupoint selection, treatment and the like is required to be 100% by checking, and the checking score is more than 95% to judge that the technology has the implementation qualification of the research technology. And the nurses who do not pass one examination need to be subjected to intensive training and then check again, and if three checks do not pass, the nurses are not considered as nurses with operation qualification.
Preparation of 10.2.2 she medicine phlegm-resolving superfine powder patch
50 parts of herbal tea, 50 parts of herba melastoma, 15 parts of ephedra, 30 parts of almond, 15 parts of ginger processed pinellia tuber, 15 parts of Chinese lute leaf, 10 parts of borneol and 10 parts of liquorice are dried at the temperature of 60 ℃, are subjected to superfine grinding, are mixed, and are blended into ointment according to 45 parts of honey, 50 parts of water and 0.95 part of herbal tea oil by weight, and before use, the ointment is coated on an ultrasonic lead-in cotton piece to prepare the superfine powder patch for eliminating phlegm of the Chinese lutea medicine.
Implementation of 10.2.3 protocol
(1) Positioning
Positioning acupoints: the Chinese medical science and the Chinese medical science are formulated by referring to the national standard of the people's republic of China, namely the acupoint names and locations (GB/T12346-2006), and the teaching materials of the national higher traditional Chinese medical institutions, namely the channel and acupoint science.
Feishu acupoint: under the spinous process of the 3 rd thoracic vertebra, 1.5 cun lateral to the back transport point of the lung, shu is the point where lung qi is transported and infused, which is the important point for treating lung diseases. Has the effects of relieving exterior syndrome, dispersing lung qi, and descending lung qi.
Pishu acupoint: under the spinous process of the 11 th thoracic vertebra, 1.5 cun lateral to the back transport point of the spleen, stimulate the back transport point to strengthen the spleen's transportation and transformation function, and play a role in strengthening the spleen and resolving phlegm.
Shenshu acupoint: under the spinous process of lumbar vertebra, 1.5 cun lateral to the back transport point of the kidney, the kidney middle-jiao essence can protect the body, prevent invasion of pathogenic factors and prevent diseases.
(2) Intervention time: the experimental group carries out she medicine acupoint ultrasonic penetration on the basis of the control group intervention scheme at the Feishu acupoint at 5:00-7:00, at the Pishu acupoint at 9:00-11:00 and at the Shenshu acupoint at 17:00-19:00. Since the lung and large intestine are both exterior and interior, the large intestine meridian qi is the most vigorous in the range of 5:00-7:00, so it is indicated for large intestine and lung.
(3) Intervention method
(1) The patients were evaluated for their main symptoms, past history, allergic history, and pregnancy. Sensory perception and local skin conditions. The notification time is typically 15 minutes, and a slight needle penetration and formic acid walking may be generated during the treatment, which is a normal phenomenon,
if the burning or needling sensation is not tolerated in the local area, the nurse is immediately notified.
(2) Article preparation
Ultrasonic medicine penetrates into therapeutic equipment, physiotherapy sheet, bandage or elastic buckle and adhesive tape.
(3) Basic operation method
Checking medical advice, evaluating a patient, making explanation, and adjusting the room temperature; the prepared article is carried beside the bed. Helping the patient to take the comfortable position and exposing the treatment part. Turning on a power switch, scooping out 4g of the prepared medicine by using a quantitative spoon, uniformly coating the medicine on a special cotton piece, placing the special cotton piece on a treatment part, fixing the medicine, turning on a power supply, and adjusting the gear step by step from small to large until the medicine is tolerated by a patient. Patient sensation is of concern in therapy. And after the treatment is finished, taking down the superfine powder paste electrode, wiping off local skin, and observing the skin condition.
(4) Notice matters
The treatment method should be used with cautions for patients with metallic foreign body at the treatment part and cardiac pacemaker; during treatment, the privacy is protected by shielding, and the warmth is kept; during the treatment process, the reaction of the patient and the running condition of the machine are observed; the skin at the treatment part has erythema, pain, blisters and the like, and the treatment should be stopped immediately and the doctor should be informed to cooperate with the treatment; the operation course is 1 time a day, 10 times is one course of treatment, and the total treatment is 1 course of treatment.
11. Adverse events
During the treatment process, patients are concerned about whether the skin is red, itching and other discomforts, the patients are clearly informed of any discomforts, and the medical staff is required to inform the medical staff and judge whether to continue to participate in the study.
12. Efficacy evaluation criteria
Standards were established with reference to the chinese adult CAP diagnostic and treatment guidelines (2018 edition). (1) healing: the clinical symptoms and signs disappear or disappear basically, and the inflammatory indexes such as WBC, N%, CRP, PCT and the like are recovered to be normal. (2) obvious effect: the clinical symptoms and signs are obviously improved, and the inflammatory indexes such as WBC, N%, CRP, PCT and the like are obviously reduced. (3) effective: the clinical symptoms and signs are improved, and the inflammatory indexes such as WBC, N%, CRP, PCT and the like are not obviously reduced. (4) ineffective: the clinical symptoms and signs are not changed or aggravated, and the inflammatory indexes such as WBC, N%, CRP, PCT and the like are not reduced or aggravated. And (3) injection: total effective rate= (cure+significant+effective)/total case number x 100%.
13. Quality control
13.1 screening subjects strictly according to inclusion exclusion criteria followed the ethical principles of voluntary, confidential, and harmless.
13.2, two groups of patients are consistent in Western medicine treatment scheme, and are subjected to consistent nursing by adopting a phlegm-heat obstructing lung type wind-warm lung-heat disease nursing scheme, so that interference of confounding factors is reduced.
13.3, making a unified operation standard of project operation, uniformly training project implementers, and checking to confirm the technical implementation of the research through the following steps: the nurses with operation qualification in the departments are trained uniformly, and the operation can be performed after the examination. According to the daily operation implementation personnel list, two high-annual resource nurses are responsible for quality supervision and control.
13.4, the evaluator performs unified training, and operates by adopting unified standards, so that subjective bias is reduced: two responsibility group companies are fixed as evaluators and trained to evaluate related data, so that unification of standards is ensured.
13.5, implementing a blind method for the evaluator, namely, the evaluator does not know the test grouping condition of the patient, collecting and evaluating the data according to the serial number of the patient as the unique number, and ensuring the objectivity and accuracy of the statistical result.
13.6 she medicine phlegm-resolving superfine powder patch is manufactured strictly according to the program requirement, and the process needs to mix and uniformly mix various medicine superfine powder with other substances such as water and the like according to the standard proportion. The low-temperature drying and the drug mixing and modulation in the early stage are finished with assistance of doctors in the national institute of medicine and the traditional Chinese medicine institute of the same three-phase traditional Chinese medicine, zhejiang province, and the operation quality of the process is controlled.
13.7 patient compliance: strengthen the education of the disease health knowledge of the patient, and lead the patient to realize the importance of the matched treatment; informing the principle and meaning of the study, and improving the coordination degree of patients; the operation executing nurse verbally encourages the patient and gives a certain gift rewards according to the requirement.
13.8, an emergency plan for adverse reaction after the she medicine phlegm reduction superfine powder patch is used is formulated.
14. Statistical analysis
The data of this study were statistically analyzed using SPSS23.0 statistical software. The measurement data result is expressed as mean ± standard deviation, the effect of time and treatment factors is compared by using two-way repeated measurement variance analysis, the sphere assumption is verified by using a Mauchly test, and if the sphere assumption is violated, the correction is performed by using a Greenhouse-Geisser method. When there is an interaction effect, then separate effect analysis is performed, and post hoc analysis is performed using the Bonferroni method. The counting data are expressed in terms of frequency and percentage, and are analyzed by chi-square test. Rank sum test is used for comparison between rank data sets. The difference was statistically significant using a two-sided test, with P < 0.05.
15. Ethical examination
The study was conducted by ethical examination of the ethical committee of medical science in Lishui, university of Zhejiang, ethical examination number (2021) Linen-to-be (LW-014), and study subjects were enrolled in the study after informed consent was signed.
2. Experimental results
Baseline data comparison of two groups of patients
In the research process, as 1 abscission case of the test group and 2 abscission cases of the control group, 75 cases of effective data are finally counted, and the abscission rate is 3.85%. The test group comprises 38 cases, wherein 20 cases are men and 18 cases are women, and the ages are 33-76; the control group had 37 cases, 18 cases for men, 19 cases for women, and ages 25 to 78.
Through statistical analysis, the two groups of patients have no statistical significance (P > 0.05) in terms of age, sex, body mass index and smoking Shi Dengcha. See in particular table 1.
Table 1 baseline data comparison for two groups of patients
Integral comparison of Chinese medical symptoms in two groups of patients
Wind-warm lung-heat syndrome integration: the three symptoms are respectively cough, expectoration, aversion to cold, fever, chest distress and chest pain, scoring is carried out according to the actual condition of a patient, and the final score is the sum of the three scores.
According to repeated measurement analysis of variance, because of interaction effect (P is less than 0.05) of intervention time and groups, independent effect analysis is carried out on traditional Chinese medicine syndrome integration, and the result shows that the difference between the test group and the control group before intervention has no statistical significance (P=0.864) and is comparable; along with the extension of the intervention time, the Chinese medicine syndrome integral of the test group and the control group gradually decreases on the 5 th and 10 th intervention days, the difference has statistical significance (F=1618.890 and P < 0.001), and the degree of decreasing the Chinese medicine syndrome integral between the two groups also has significant difference (F=4.079 and P < 0.05). In summary, the integral of the traditional Chinese medicine symptoms of the two groups gradually decreases along with the time, and the effect of improving the integral of the traditional Chinese medicine symptoms of the test group is better than that of the control group. See in particular table 2.
TABLE 2 integral comparison of Chinese medical symptoms for two groups of patients
Dividing into two parts
Comparison of CPIS scores for pulmonary infections in two groups of patients
Lung infection CPIS score: is a scoring system which integrates clinical, imaging and microbiologic standards to evaluate the severity of infection, and is divided into 12 at most; the higher the score, the heavier the condition.
As a result of repeated analysis of variance, interaction effects (P < 0.05) exist in the intervention time and the groups, so that independent effect analysis is carried out on the CPIS scores, and the result shows that the difference between the CPIS scores before the intervention of the two groups has no statistical significance (p=0.544) and is comparable; as the intervention time was prolonged, the CPIS scores of both the test and control groups were gradually decreased, the difference was statistically significant (f=2569.096, p < 0.001), and there was also a significant difference in the extent to which the CPIS scores were decreased between the two groups (f=4.226, p < 0.05). In summary, both groups had lung infections with a gradually decreasing CPIS score over time, and the decrease in the test group was superior to the control group. See in particular table 3.
TABLE 3 comparison of CPIS scores for two groups of patients with pulmonary infections
Dividing into two parts
Comparison of inflammation index for two groups of patients
According to repeated analysis of variance, interaction effect exists in intervention time and groups (P < 0.05), so that independent effect analysis is carried out on the percent of neutrophil (N%), the hypersensitive C-reactive protein (CRP) and the procalcitonin value (PCT), and the results show that before intervention, the differences of N%, CRP and PCT of the two groups have no statistical significance (P > 0.05) and are comparable; over time, the dry prognosis of the test and control groups was progressively lower in N%, CRP, PCT than before the intervention, the difference was statistically significant (both P < 0.001), and there was also a significant difference in the extent to which CPIS scores were reduced between the two groups (both P < 0.05). In summary, the inflammation index of both groups gradually decreased with time, and the decrease effect of the test group was better than that of the control group. See in particular table 4.
Table 4 comparison of inflammation index for two groups of patients
Comparison of clinical efficacy in two groups of patients
According to clinical judgment standards, 35 patients in the test group are clinically effective, and the total effective rate is 92.11%; 30 patients in the control group are clinically effective, the total effective rate is 81.08%, the clinical curative effects of the two patients are statistically significant, and the curative effects of the test group are better than those of the control group (Z=2.329 and P=0.020), and the specific results are shown in Table 5.
Table 5 comparison of clinical efficacy for two groups of patients [ example (%)
(sixth) evaluation of safety
During the study period, the control group dropped 2 cases and the test group dropped 1 case. The patient in the test group had red skin on the 3 rd day of intervention, was sterilized with a pre-iodophor cotton swab, and was gently rubbed against the skin with a 0.9% saline cotton swab for 1 day 2 times, and was returned to normal on the 5 th day, so the test was exited and the nurse continued to follow up with the skin condition.
3. Analysis of study results
The study is obtained by the comparison between the test group and the control group on the 5 th day and the 10 th day of intervention, the traditional Chinese medicine syndrome integral, the lung infection CPIS score, the neutrophil percentage, the CRP and procalcitonin comparison group difference are all statistically significant (P is less than 0.05), and the superfine powder patch superfine powder of the traditional Chinese medicine for resolving phlegm has a better treatment effect on the patients with phlegm-heat obstructing lung type wind-warm lung-heat disease through acupoint ultrasonic penetration treatment;
as can be seen from the comparison of the two groups of curative effects, the total effective rate of the test group is 92.11%; the total effective rate of the control group is 81.08%, and the curative effect of she medicine acupoint ultrasonic penetration on treating phlegm-heat accumulated lung type wind-warm lung-heat disease is better than that of the control group (Z=2.329, P=0.020). Ultrasonic medicine penetration treatment is to enhance transdermal transmission of a plurality of medicines including macromolecular medicines, improve skin penetration capacity, raise local medicine concentration and better exert the medicine effect of she medicine.
In conclusion, the curative effect of the she medicine phlegm-resolving superfine powder on the acupoint ultrasonic penetration treatment of the patients with phlegm-heat obstructing lung type wind-warm lung-heat disease is better than that of the conventional Western medicine treatment nursing.
2. The she medicine phlegm-resolving superfine powder is stuck on superfine powder and is subjected to acupoint ultrasonic penetration treatment to intervene on phlegm-heat obstructing lung type wind-warm lung-heat disease for 10 days rather than 5 days
The differences between the three time points of the traditional Chinese medicine syndrome score, CPIS score, neutrophil percentage, hypersensitive C-reactive protein and procalcitonin of the two groups of patients are all statistically significant (P < 0.001). The she medicine phlegm-resolving superfine powder can reduce the traditional Chinese medicine syndrome integral and CPIS score, and reduce the percentage of neutrophil in blood, hypersensitive C reactive protein, procalcitonin, etc. Meanwhile, the indexes of the intervention for 10 days and the indexes of the intervention for 5 days are compared with each other in time effect, and the result shows that the indexes of the intervention for 10 days are better than the indexes of the treatment for 5 days. This shows that with the extension of the intervention time, the she medicine phlegm-resolving superfine powder is more fully applied to the patient subjected to acupoint ultrasonic penetration treatment, and the traditional Chinese medicine effect is more remarkable.
4. Conclusion(s)
The ultra-micro powder acupoint ultrasonic penetration of the she medicine phlegm-resolving formula can obviously improve the traditional Chinese medicine syndrome integration of the patient with phlegm-heat accumulation lung type wind-warm lung-heat disease, effectively reduce the lung infection CPIS score and relevant inflammatory indexes (N%, CRP and PCT) of the patient, effectively improve the clinical curative effect, and is worthy of clinical popularization and application.
The foregoing description of the preferred embodiments of the invention is not intended to limit the invention, but rather to enable any modification, equivalent replacement, improvement or the like to be included within the spirit and principles of the invention.
Claims (4)
1. The she medicine phlegm-resolving superfine powder patch is characterized by comprising the following medicinal components in parts by weight: 45-55 parts of cold tea (she), 45-55 parts of melastoma dodecandrum, 10-20 parts of ephedra herb, 25-35 parts of almond, 10-20 parts of ginger processed pinellia tuber, 10-20 parts of loquat leaf, 5-15 parts of borneol and 5-15 parts of liquorice.
2. The she medicine phlegm-resolving superfine powder patch as claimed in claim 1, wherein the she medicine phlegm-resolving superfine powder patch comprises the following components in parts by weight: 50 parts of cold tea (she), 50 parts of melastoma, 15 parts of ephedra herb, 30 parts of almond, 15 parts of ginger processed pinellia, 15 parts of loquat leaf, 10 parts of borneol and 10 parts of liquorice.
3. The preparation method of the she medicine phlegm-resolving superfine powder patch is characterized in that the medicine of the she medicine phlegm-resolving superfine powder patch in claim 2 is dried at the temperature of 60 ℃, superfine crushed and mixed, 45 parts of honey, 50 parts of water and 0.95 part of cool tea oil are blended into ointment by weight, and before use, the ointment is coated on an ultrasonic imported cotton piece to prepare the she medicine phlegm-resolving superfine powder patch.
4. The preparation method of the she medicine phlegm-resolving superfine powder patch according to claim 3, wherein the she medicine phlegm-resolving superfine powder patch has a diameter of 3.7cm and a thickness of 2mm, and the weight of each she medicine phlegm-resolving superfine powder patch is 4g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211346714.9A CN115634250B (en) | 2022-10-31 | 2022-10-31 | She medicine phlegm-resolving superfine powder patch and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211346714.9A CN115634250B (en) | 2022-10-31 | 2022-10-31 | She medicine phlegm-resolving superfine powder patch and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115634250A CN115634250A (en) | 2023-01-24 |
| CN115634250B true CN115634250B (en) | 2023-06-20 |
Family
ID=84946175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211346714.9A Active CN115634250B (en) | 2022-10-31 | 2022-10-31 | She medicine phlegm-resolving superfine powder patch and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115634250B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721429A (en) * | 2015-03-27 | 2015-06-24 | 福建省漳州市中医院 | Chinese medicinal externally-used patch for treating cough and asthma due to accumulation of phlegm and heat in lung and preparation method thereof |
| CN105267522A (en) * | 2015-11-23 | 2016-01-27 | 许世钦 | Phlegm reducing patch for treating cough and asthma |
-
2022
- 2022-10-31 CN CN202211346714.9A patent/CN115634250B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104721429A (en) * | 2015-03-27 | 2015-06-24 | 福建省漳州市中医院 | Chinese medicinal externally-used patch for treating cough and asthma due to accumulation of phlegm and heat in lung and preparation method thereof |
| CN105267522A (en) * | 2015-11-23 | 2016-01-27 | 许世钦 | Phlegm reducing patch for treating cough and asthma |
Non-Patent Citations (1)
| Title |
|---|
| 12种畲药的研究进展;范蕾等;中国药师;第19卷(第07期);1374-1377 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115634250A (en) | 2023-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lindwall et al. | Depression and exercise in elderly men and women: findings from the Swedish national study on aging and care | |
| Li et al. | Bu-Fei Yi-Shen granule combined with acupoint sticking therapy in patients with stable chronic obstructive pulmonary disease: a randomized, double-blind, double-dummy, active-controlled, 4-center study | |
| Mohammad et al. | A study of electrolyte disturbances in patients with chronic stable asthma and with asthma attacks | |
| Fortuna et al. | Diagnostic utility of inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count | |
| Liyun et al. | Efficacy and safety of Liangxue Jiedu decoction for the treatment of progressive psoriasis vulgaris: a multicenter, randomized, controlled study. | |
| Jimenez et al. | Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study | |
| Sankhe et al. | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India | |
| CN115634250B (en) | She medicine phlegm-resolving superfine powder patch and preparation method thereof | |
| Ryan | Asthma and rhinitis: comorbidities | |
| Li et al. | Clinical practice guidelines and experts’ consensuses for treatment of coronavirus disease 2019 (COVID-19) patients with Chinese herbal medicine: a systematic review | |
| Li et al. | Transplantation of autologous peripheral blood mononuclear cells in the subarachnoid space for amyotrophic lateral sclerosis: a safety analysis of 14 patients | |
| Wang et al. | The impact of health education on the self-care ability of patients with peptic ulcer disease | |
| Shao et al. | Hemoptysis caused by Parvimonas micra: case report and literature review | |
| Zu et al. | Effects of the Chinese herbal formula San-Huang Gu-Ben Zhi-Ke treatment on stable chronic obstructive pulmonary disease: study protocol of a randomized, double-blind, placebo-controlled trial | |
| Abdolahinia et al. | Effect of Nepeta bracteata benth. on chronic obstructive pulmonary disease: a triple-blinded, randomized clinical trial | |
| CN112138084A (en) | Traditional Chinese medicine formula for treating bronchiectasis syndrome of qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| Liu et al. | [Retracted] Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes | |
| Jurecek et al. | Beneficial effects of an alkaline topical treatment in patients with mild atopic dermatitis | |
| Corren | The influence of upper airway disease on the lower airway | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| Ramadan Shepl Ali et al. | Effect of Oral Care and Relaxation Technique on Gastrointestinal Tract Problems of Patients Undergoing Chemotherapy | |
| CN107158167B (en) | Traditional Chinese medicine film for treating necrotizing lymphadenitis and preparation method thereof | |
| Junjie et al. | Jinye Baidu granule for wind-warmth lung-heat disease (heat in the lung-wei): protocol for a randomized, double-blind, parallel, controlled trial | |
| Hu et al. | Efficacy evaluation of high-frequency ultrasound in the treatment of diabetic peripheral neuropathy with a-lipoic acid combined with traditional Chinese medicine package treatment. | |
| Ma et al. | Efficacy and safety of Lianhua Qingwen granule in the treatment of non-influenza viral pneumonia: a randomized, double-blind, placebo-controlled, multicenter clinical study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |